C3 Glomerulopathy
📧 Sign up to get email alerts when something new happens for C3 Glomerulopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted [Phase 2]
Phase 2 trial evaluating efficacy and safety of LNP023 in C3 glomerulopathy patients, including transplanted and non-transplanted cohorts, h…
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) [Phase 2]
Phase 2 proof-of-concept trial of danicopan for six months in participants with C3 glomerulopathy has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN [Phase 2]
Phase 2 trial assessing danicopan effects on C3 levels in participants with C3 glomerulopathy or IC-MPGN; the study is completed with result…
-
CLINICAL_TRIALS withdrawal · 2016-10-27Clinical Trial Update: TP10 Use in Patients With C3 Glomerulopathy (C3G) [Phase 1]
A Phase 1 trial of TP10 in patients with C3 glomerulopathy (Dense Deposit Disease) has been withdrawn.